DRUG · Mapped RxNorm record
avelumab
Normalized identity: avelumab View linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors
NCT04052204
Study summary
ClinicalTrials.govAvelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors
Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE1, PHASE2
Loading study purpose, treatment groups and outcomes…
View the complete registry record, eligibility and contacts at ClinicalTrials.gov
Drugs and interventions used in this trial
4 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Unmapped registry intervention
Bempegaldesleukin
Find medicine records ·
Find other trials using this name
DRUG · Mapped RxNorm record
talazoparib
Normalized identity: talazoparib View linked drug · Find medicine records ·
Find other trials using this name
DRUG · Mapped RxNorm record
enzalutamide
Normalized identity: enzalutamide View linked drug · Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Advertisement
Conditions
Interventions
avelumabDRUG · verified · RxNorm: avelumab
talazoparibDRUG · verified · RxNorm: talazoparib
enzalutamideDRUG · verified · RxNorm: enzalutamide
Sponsors & collaborators
Pfizerlead sponsor
EMD Seronocollaborator
Nektar Therapeuticscollaborator
Astellas Pharma Inccollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04052204 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.